Novartis AG [NYSE: NVS] plunged by -$0.09 during the normal trading session on Thursday and reaching a high of $83.60 during the day while it closed the day at $83.46. The company report on November 7, 2022 that New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (LDL-C) over four years of treatment1,2.
At any time throughout the trial, approximately 80% of patients reached an LDL-C level of <70mg/dL2. Novartis AG stock has also loss -1.96% of its value over the past 7 days. However, NVS stock has declined by -2.68% in the 3 months of the year. Over the past six months meanwhile, it has lost -5.85% and lost -4.58% year-on date. The market cap for NVS stock reached $199.70 billion, with 2.17 billion shares outstanding and 2.15 billion shares in the current float. Compared to the average trading volume of 2.44M shares, NVS reached a trading volume of 2211587 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novartis AG [NVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVS shares is $100.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVS stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Novartis AG shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on September 15, 2022. The new note on the price target was released on September 14, 2022, representing the official price target for Novartis AG stock.
The Average True Range (ATR) for Novartis AG is set at 1.32, with the Price to Sales ratio for NVS stock in the period of the last 12 months amounting to 3.82. The Price to Book ratio for the last quarter was 2.97, with the Price to Cash per share for the same quarter was set at 7.98. Price to Free Cash Flow for NVS in the course of the last twelve months was 38.10 with Quick ratio for the last quarter at 1.10.
NVS stock trade performance evaluation
Novartis AG [NVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.96. With this latest performance, NVS shares gained by 9.08% in over the last four-week period, additionally sinking by -5.85% over the last 6 months – not to mention a rise of 1.90% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVS stock in for the last two-week period is set at 63.42, with the RSI for the last a single of trading hit 64.22, and the three-weeks RSI is set at 60.51 for Novartis AG [NVS]. The present Moving Average for the last 50 days of trading for this stock 79.14, while it was recorded at 83.66 for the last single week of trading, and 84.39 for the last 200 days.
Novartis AG [NVS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Novartis AG [NVS] shares currently have an operating margin of +23.11 and a Gross Margin at +69.27. Novartis AG’s Net Margin is presently recorded at +46.53.
Return on Total Capital for NVS is now 12.56, given the latest momentum, and Return on Invested Capital for the company is 27.67. Return on Equity for this stock inclined to 39.33, with Return on Assets sitting at 18.25. When it comes to the capital structure of this company, Novartis AG [NVS] has a Total Debt to Total Equity ratio set at 45.86. Additionally, NVS Total Debt to Total Capital is recorded at 31.44, with Total Debt to Total Assets ending up at 22.83. Long-Term Debt to Equity for the company is recorded at 36.25, with the Long-Term Debt to Total Capital now at 24.85.
Reflecting on the efficiency of the workforce at the company, Novartis AG [NVS] managed to generate an average of $210,515 per employee. Receivables Turnover for the company is 5.88 with a Total Asset Turnover recorded at a value of 0.39.Novartis AG’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.
Earnings per share (EPS) analysis for Novartis AG [NVS] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novartis AG go to 3.56%.
Novartis AG [NVS]: Insider Ownership positions
There are presently around $15,276 million, or 8.80% of NVS stock, in the hands of institutional investors. The top three institutional holders of NVS stocks are: DODGE & COX with ownership of 21,048,657, which is approximately -6.669% of the company’s market cap and around 9.30% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 17,453,150 shares of the stock with an approximate value of $1.46 billion in NVS stocks shares; and LOOMIS SAYLES & CO L P, currently with $1.25 billion in NVS stock with ownership of nearly -3.587% of the company’s market capitalization.
Positions in Novartis AG stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 395 institutional holders increased their position in Novartis AG [NYSE:NVS] by around 5,717,617 shares. Additionally, 553 investors decreased positions by around 24,702,452 shares, while 246 investors held positions by with 152,618,986 shares. The mentioned changes placed institutional holdings at 183,039,055 shares, according to the latest SEC report filing. NVS stock had 63 new institutional investments in for a total of 1,052,232 shares, while 92 institutional investors sold positions of 2,127,124 shares during the same period.